Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein

No Thumbnail Available
File version
Author(s)
Xu, Ming-ming
Ryan, Philip
Rudrawar, Santosh
Quinn, Ronald J
Zhang, Hai-yan
Mellick, George D
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
License
Abstract

Abnormal protein aggregation has been linked to many neurodegenerative diseases, including Parkinson’s disease (PD). The main pathological hallmark of PD is the formation of Lewy bodies (LBs) and Lewy neurites, both of which contain the presynaptic protein alpha-synuclein (α-syn). Under normal conditions, native α-syn exists in a soluble unfolded state but undergoes misfolding and aggregation into toxic aggregates under pathological conditions. Toxic α-syn species, especially oligomers, can cause oxidative stress, membrane penetration, synaptic and mitochondrial dysfunction, as well as other damage, leading to neuronal death and eventually neurodegeneration. Early diagnosis and treatments targeting PD pathogenesis are urgently needed. Given its critical role in PD, α-syn is an attractive target for the development of both diagnostic tools and effective therapeutics. This review summarizes the progress toward discovering imaging probes and aggregation inhibitors for α-syn. Relevant strategies and techniques in the discovery of α-syn-targeted drugs are also discussed.

Journal Title

Acta Pharmacologica Sinica

Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note

This publication has been entered into Griffith Research Online as an Advanced Online Version.

Access the data
Related item(s)
Subject

Pharmacology and pharmaceutical sciences

Parkinson’s disease

aggregation inhibitors

alpha-synuclein

imaging probes

mass spectrometry

Persistent link to this record
Citation

Xu, MM; Ryan, P; Rudrawar, S; Quinn, RJ; Zhang, HY; Mellick, GD, Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein, Acta Pharmacologica Sinica, 2019

Collections